MedTrace Logo

Plasma Myeloperoxidase Levels in Patients With Coronary Artery Disease

NCT01239979 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2010-12-22

No results posted yet for this study

Summary

The investigators sought to assess whether plasma myeloperoxidase (MPO) levels differ among patients with stable and unstable CAD patients and control subjects, and correlate with inflammatory and clinical risk factors such as ox-LDL, NO,leptin, adiponectin, sPLA2, Lp-PLA2, homocysteine and 3-nitrotyrosine in the patients.

Conditions

Sponsors & Collaborators

  • Isfahan University of Medical Sciences

    lead OTHER

Principal Investigators

  • Saedzaaldin Samsamshariat, PhD · - Clinical Biochemistry Department, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran

Eligibility

Min Age
35 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2010-03-31
Completion
2010-11-30

Countries

  • Iran

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01239979 on ClinicalTrials.gov